Cargando…

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo

The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Roulin, Didier, Cerantola, Yannick, Dormond-Meuwly, Anne, Demartines, Nicolas, Dormond, Olivier
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850884/
https://www.ncbi.nlm.nih.gov/pubmed/20226010
http://dx.doi.org/10.1186/1476-4598-9-57
_version_ 1782179814016286720
author Roulin, Didier
Cerantola, Yannick
Dormond-Meuwly, Anne
Demartines, Nicolas
Dormond, Olivier
author_facet Roulin, Didier
Cerantola, Yannick
Dormond-Meuwly, Anne
Demartines, Nicolas
Dormond, Olivier
author_sort Roulin, Didier
collection PubMed
description The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In this study, we explored the specific role of mTORC2 in colon cancer using a short hairpin RNA expression system to silence the mTORC2-associated protein rictor. We found that downregulation of rictor in HT29 and LS174T colon cancer cells significantly reduced cell proliferation. Knockdown of rictor also resulted in a G1 arrest as observed by cell cycle analysis. We further observed that LS174T cells deficient for rictor failed to form tumors in a nude mice xenograft model. Taken together, these results show that the inhibition of mTORC2 reduces colon cancer cell proliferation in vitro and tumor xenograft formation in vivo. They also suggest that specifically targeting mTORC2 may provide a novel treatment strategy for colorectal cancer.
format Text
id pubmed-2850884
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28508842010-04-08 Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo Roulin, Didier Cerantola, Yannick Dormond-Meuwly, Anne Demartines, Nicolas Dormond, Olivier Mol Cancer Short communication The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In this study, we explored the specific role of mTORC2 in colon cancer using a short hairpin RNA expression system to silence the mTORC2-associated protein rictor. We found that downregulation of rictor in HT29 and LS174T colon cancer cells significantly reduced cell proliferation. Knockdown of rictor also resulted in a G1 arrest as observed by cell cycle analysis. We further observed that LS174T cells deficient for rictor failed to form tumors in a nude mice xenograft model. Taken together, these results show that the inhibition of mTORC2 reduces colon cancer cell proliferation in vitro and tumor xenograft formation in vivo. They also suggest that specifically targeting mTORC2 may provide a novel treatment strategy for colorectal cancer. BioMed Central 2010-03-12 /pmc/articles/PMC2850884/ /pubmed/20226010 http://dx.doi.org/10.1186/1476-4598-9-57 Text en Copyright ©2010 Roulin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short communication
Roulin, Didier
Cerantola, Yannick
Dormond-Meuwly, Anne
Demartines, Nicolas
Dormond, Olivier
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
title Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
title_full Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
title_fullStr Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
title_full_unstemmed Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
title_short Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
title_sort targeting mtorc2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
topic Short communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850884/
https://www.ncbi.nlm.nih.gov/pubmed/20226010
http://dx.doi.org/10.1186/1476-4598-9-57
work_keys_str_mv AT roulindidier targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo
AT cerantolayannick targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo
AT dormondmeuwlyanne targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo
AT demartinesnicolas targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo
AT dormondolivier targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo